Peptides DB
Research-centric peptide and protocol reference hub

DNSP-11 (Dopamine Neuron Stimulating Peptide-11) record · updated 20h ago

Neuro & moodHealing & recoveryGrade B · human evidenceResearch use only
All 14 studiesJump to the evidenceCompare
What is DNSP-11 (Dopamine Neuron Stimulating Peptide-11) used for?

DNSP-11 is an 11-amino-acid peptide derived from the GDNF pro-region, studied preclinically for its neurotrophic effects on dopaminergic neurons in Parkinson's disease research models.

Primarily researched for · Neuro & mood

Development stage

where DNSP-11 (Dopamine Neuron Stimulating Peptide-11) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus. It describes the research record, not a recommendation.

Identity
NameDNSP-11 (Dopamine Neuron Stimulating Peptide-11)
Chain length—
Molecular weight—
Formula—
Structure type—
ClassCognitive
Research levelLimited Research
Discovered byCurated master list · 2026
Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 14, 2026. How this works →
Research stats
Total studies14
Human / animal / cellular3 / 8 / 0
Highest trial phasePreclinical
Years covered2011–2026
Latest study17d ago
Publication history
20112026
Research funding
14 NIH projects · $5.6M awarded · through FY2024
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

14 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Mutations in feline infectious peritonitis virus nonstructural protein 14/16 methyltransferase attenuate the pathogenicity of the virus in cats.
Finding75% reduction in mortality compared to wild type.
Animal2025Full text read0.70
Tailoring malaria control interventions to suit local context: codesign of perennial malaria chemoprevention (PMC) programmes through the Plus Project.
FindingNot reported in abstract.
review2024Full text read0.70
The influence of public health organization on response to the COVID-19 pandemic in four Canadian provinces: A comparative qualitative analysis.
FindingNot reported in abstract.
review2025Full text read0.80
Exploring drug coverage variability within districts: A CES approach to investigate treatment gaps in Mozambique's schistosomiasis program.
FindingEffective programmatic coverage (≥75%) achieved with 95% confidence in five districts.
review2023Full text read0.80
Challenges and opportunities to addressing non-communicable diseases after climate-related disasters in Mozambique: a qualitative study.
FindingNot reported in abstract.
Human2026Full text read0.70
Comparison of short nasal swab and deep nasopharyngeal swab sampling methods to describe BRD-associated viruses and bacteria detected using a metagenomics approach optimized for virus recovery in fall-placed beef calves shortly after feedlot arrival.
Findingmean reads for BCoV: 75 vs 17; OR = 21.4, p = 0.001
Animal2026Full text read0.80
Identification of novel GDNF isoforms and cis-antisense GDNFOS gene and their regulation in human middle temporal gyrus of Alzheimer disease.
FindingMature GDNF peptide down-regulated in AD patients compared to normal controls.
Human2011Full text read0.70
A synthetic five amino acid propeptide increases dopamine neuron differentiation and neurochemical function.
FindingApproximately 66% increase in extracellular DA levels compared to vehicle.
Animal2013Full text read0.80
Dynamic changes in dopamine neuron function after DNSP-11 treatment: effects in vivo and increased ERK 1/2 phosphorylation in vitro.
FindingNot reported in abstract.
Animal2013Full text read0.80
Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease.
Finding300μg DNSP-11 increased dopamine turnover in striatum and substantia nigra in normal rats over 3 weeks.
Animal2015Full text read0.80
Methodology and effects of repeated intranasal delivery of DNSP-11 in awake Rhesus macaques.
FindingNot reported in abstract.
Animal2018Full text read0.70
Spatial and temporal immunoreactivity in the rat brain using an affinity purified polyclonal antibody to DNSP-11.
FindingNot reported in abstract.
Animal2019Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching DNSP-11 (Dopamine Neuron Stimulating Peptide-11) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much DNSP-11 (Dopamine Neuron Stimulating Peptide-11) is discussed should be drawn from it.